Clinical Report: FDA broadens APDS treatment options
Overview
The FDA has approved leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in pediatric patients aged 4 to 11 years.
Background
Activated phosphoinositide 3-kinase delta syndrome (APDS) is a rare genetic disorder characterized by immune system dysfunction, leading to recurrent infections and potential organ enlargement. The recent FDA approval of leniolisib for younger patients expands treatment options for this condition.
Data Highlights
No numerical data available in the provided source material.
Key Findings
The FDA approved leniolisib for pediatric patients aged 4 to 11 years with APDS.
Leniolisib was previously approved for patients aged 12 years and older in 2023.
Study 2201 demonstrated significant efficacy in reducing lymphadenopathy and improving naïve B-cell counts in older patients.
Common adverse effects in younger patients include abdominal pain, respiratory tract infection, and diarrhea.
Patients with moderate to severe liver impairment should not receive leniolisib.
Clinical Implications
Clinicians should be aware of the specific dosing and safety considerations for pediatric patients receiving leniolisib.
Conclusion
The FDA's approval of leniolisib for younger patients with APDS provides a new treatment option for this rare genetic disorder.
